New hope for frail lung cancer patients: immunotherapy drug tested
NCT ID NCT04108026
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the immunotherapy drug durvalumab in 50 patients with advanced lung cancer who were too weak for standard chemotherapy. The goal was to see if the drug is safe and helps control the disease. Researchers focused on side effects and how well patients responded.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug)
What this could lead to
If successful, this could offer a treatment option for lung cancer patients who are too frail for standard chemotherapy, potentially improving survival and quality of life.
What could go wrong
This is a small, single-arm Phase 2 trial with only 50 participants, so results may not apply broadly. The drug may cause serious side effects, and there is no comparison group to confirm benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM Hopital Nord
Marseille, France
-
AP-HP Hopital Tenon - Pneumologie
Paris, 75020, France
-
Besançon - CHU
Besançon, France
-
CH
Colmar, France
-
CHR d'Orléans La Source
Orléans, France
-
CHRU Grenoble
Grenoble, France
-
CHRU de Lille
Lille, France
-
CHU Strasbourg
Strasbourg, France
-
CHU Toulouse - Pneumologie
Toulouse, France
-
CHU Tours - Pneumologie
Tours, France
-
Caen - CHU Côte de Nacre
Caen, 14000, France
-
Centre Hospitalier - Pneumologie
Le Mans, 72000, France
-
GRH Mulhouse Sud-Alsace
Mulhouse, France
-
Hôpital Ambroise Paré - Pneumologie
Boulogne, France
-
Lyon - URCOT
Pierre-Bénite, France
-
Montpellier - CHRU
Montpellier, 34295, France
-
Nancy - Institut de Cancérologie de Lorraine
Nancy, France
-
Nantes - ICO Site René Gauducheau
Nantes, 44805, France
-
Paris - APHP Bichat
Paris, France
-
Paris - Curie
Paris, France